TLC-ART Program

TLC-ART Program – To Clear HIV

Targeted Long Acting Therapy intended to clear virus in tissues

  • A Dose of HIV Treatment Lasting 2 Weeks

Welcome to the University of Washington Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program. We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes. We hope to maximally suppress HIV and potentially contribute to a cure for AIDS.

School of Pharmacy School of Medicine Institute for Translational Health Sciences Seattle Children's Harborview Fred Hutch Center for AIDS Research

Our researchers were the first to document pharmacological drug deficiency with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program, with its 11 projects, intends to overcome pharmacological drug deficiency by developing a novel formulation of a combination of antiretroviral agents. TLC-ART is a publicly funded, National Institutes of Health (NIH) Supported program with contributions from multiple institutions. This program is managed by the University of Washington Department of Pharmaceutics.

We welcome your input, research support, participation and donations by either making a gift or donating directly to our faculty or students.